Kelyniam Global Inc - KLYG STOCK NEWS

Kelyniam Global (OTC: KLYG), a manufacturer of custom cranial implants, reported a 13.2% increase in total revenue for 2022, reaching $3,017,599 compared to $2,664,434 in 2021. However, the company recorded a net loss of $97,560 after posting a net income of $201,741 in the previous year. The decline in profitability was attributed to non-cash legacy stock awards and operating income fell to $69,322 from $180,445. CEO Ross Bjella highlighted the company's competitive edge in manufacturing and rapid delivery of custom implants and outlined plans for future product development and licensing in the neurosurgery market.

Kelyniam Global (OTC:KLYG) announced strong third-quarter results for the period ending September 30, 2022. Total revenue reached $2,194,435, marking a 12.3% increase year-over-year, with a gross margin of $1,738,733, up 16.4%. However, operating income decreased to $93,523 from $140,568 due to ongoing investments in infrastructure and regulatory consulting. Kelyniam also formed a partnership with Singular Health (ASX:SHG) as their Registered Agent in the U.S. following the 510(k) clearance of their innovative 3DiCom MD software.

Kelyniam Global (OTC:KLYG), a producer of custom cranial implants, reported a strong Q2 2022 with a 20% revenue increase to $1,469,354, compared to $1,224,059 in Q2 2021. The CustomizedBone® implant significantly contributed to this growth. Operating income was $38,394, slightly down from $47,167 in the same period last year. Investments in infrastructure and marketing were funded without additional debt. The company anticipates continued sales momentum and benefits from returning surgical activity trends.

Kelyniam Global (OTC: KLYG) has appointed Desiree Webb as Vice President of Sales and Strategic Development. Webb, a current Board Member, brings over 20 years of healthcare experience, previously serving as Vice President of Orthopedics and Neuroscience at HCA Healthcare. Her focus will be on boosting the growth of craniofacial implants through collaboration with surgeons and distributors, alongside strengthening existing partnerships and expanding the product line. Kelyniam specializes in custom cranial and maxillo-facial implants, leveraging advanced medical-grade polymers.

Kelyniam Global (OTC:KLYG) announced its Q1 2022 results, revealing total revenue of $656,858, down 0.1% from $664,353 in Q1 2021. The gross margin slightly improved to $509,201 from $505,326, while operating income showed a loss of $5,924 compared to a profit of $13,806 a year earlier. CEO Ross Bjella noted that revenue figures were influenced by previous COVID-related demand, and he anticipates growth from the launch of CustomizedBone. The company is enhancing its sales team to target new contracts.

Kelyniam Global (OTC: KLYG) reported a record year in 2021, showcasing a 6.06% increase in total revenue to $2,664,434 and a remarkable 363.2% surge in operating income to $180,445. Net income rose by 43% to $201,741. The company announced a new strategic partnership with Fin-ceramica and received a patent for its Integrated Fixation System, enhancing its product offerings and intellectual property. Despite operational challenges from COVID-19, Kelyniam remains committed to growth and quality improvements, with the hiring of a new VP in Quality and Regulatory Affairs.

Kelyniam Global, Inc. (OTC: KLYG) announced a strategic licensing agreement with Fin-ceramica faenza spa to market a hydroxyapatite cranial implant. This product utilizes a bio-mimetic ceramic biomaterial, mainly consisting of hydroxyapatite, which enhances osteointegration and reduces post-operative infections compared to titanium implants. The CustomizedBone Service™ implant will be distributed by Kelyniam's salesforce of over 50 representatives starting in January. This partnership aligns with both companies' focus on innovative, patient-centered technology.

Kelyniam Global has received a US patent for its Integrated Fixation Tabs, enhancing its custom cranial implant offerings. The patent, filed in 2014 and valid until 2037, covers the inclusion of fixation appendages, potentially reducing surgical costs and time by eliminating the need for plates and screws. CEO Ross Bjella emphasizes that this innovation underscores Kelyniam's commitment to advancing medical technology. The company collaborates closely with surgeons to optimize implant placement, which can result in better cosmetic outcomes for patients.

Kelyniam Global (OTC:KLYG) reported third-quarter results for the period ended September 30, 2021. Despite a 0.9% revenue decline year-over-year to $1,953,267, the company experienced strong quarterly sales growth that offset earlier pandemic-related delays. Gross margin increased to $1,494,067, and net income rose to $222,353 compared to $117,651 last year. The company’s shares were upgraded to ‘Pink Current’ status on November 5, enhancing trading liquidity. Additionally, a $144,000 Paycheck Protection Plan loan was forgiven, benefiting the financials.